Agnico Eagle Mines Ltd vs Sana Biotechnology Inc — how do they compare? Agnico Eagle Mines Ltd trades at $185.5 (market cap $92.01B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Agnico Eagle Mines Ltd is far larger — about 81.4× Sana Biotechnology Inc's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AEM | SANA | |
|---|---|---|
Market Cap | $92.01B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $5.92 |
52-Week Low | $130.23 | $2.68 |
Enterprise Value | $88.85B | $1.05B |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
AEM trades at $185.71, up 2.9% over the past day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $11.91 billion in 2025, with a net income margin of 40.44%, and maintains a solid balance sheet with total assets of $29.99 billion. Recent news highlights record free cash flow and a 20-30% gold production growth target through organic expansion.
The stock offers upside to the consensus price target of $219.63, supported by strong profitability and analyst optimism, but faces risks from rising costs and gold price volatility. With 67.74% of analysts rating it a buy, AEM remains a compelling play on gold, though investors should monitor cost pressures and production guidance.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Latest headlines on both assets
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →